Mouse Monoclonal DR4 antibody - conjugated to FITC. Suitable for IP, Flow Cyt, FuncS and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF10A.
pH: 7.4
Preservative: 0.097% Sodium azide
Constituents: 0.2% BSA
| IP | Flow Cyt | FuncS | |
|---|---|---|---|
| Human | Expected | Expected | Expected |
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info - | Notes ab91356 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info - | Notes in cultivation medium. Final concentration of TRAIL: 20-200 ng/ml. Note: It is recommended that the antibody is added 15 min before the addition of TRAIL. |
Select an associated product type
Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:26457518, PubMed:38532423). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis (PubMed:19090789). Promotes the activation of NF-kappa-B (PubMed:9430227).
CD261, APO2, DR4, TRAILR1, TNFRSF10A, Tumor necrosis factor receptor superfamily member 10A, Death receptor 4, TNF-related apoptosis-inducing ligand receptor 1, TRAIL receptor 1, TRAIL-R1
Mouse Monoclonal DR4 antibody - conjugated to FITC. Suitable for IP, Flow Cyt, FuncS and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF10A.
pH: 7.4
Preservative: 0.097% Sodium azide
Constituents: 0.2% BSA
The antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines.
The antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography).
Do not use after expiration date stamped on vial label.
Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions
must be verified by the user.
Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.
The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.
DR4 also known as TRAIL-R1 is a receptor with a molecular weight of approximately 60 kDa. It is part of the tumor necrosis factor receptor (TNFR) superfamily. DR4 is widely expressed in various types of tissues such as the liver spleen thymus and peripheral blood leukocytes. It functions mechanically by binding to its ligand TNF-related apoptosis-inducing ligand (TRAIL) which initiates signaling cascades that lead to apoptosis or programmed cell death.
The death receptor 4 plays an important role in mediating cell apoptosis. Upon ligand binding DR4 interacts with the adapter molecule FADD (FAS-associated protein with death domain) facilitating the formation of the death-inducing signaling complex (DISC). This complex recruits and activates caspase-8 which eventually leads to the activation of the downstream effector caspases driving the cell towards apoptosis. DR4 operates as a significant component of the extrinsic pathway of apoptosis a process important for maintaining cellular homeostasis and eliminating harmful cells.
DR4 functions critically within the extrinsic apoptotic pathway. This pathway involves other death receptors such as DR5 which also binds TRAIL similarly leading to apoptosis through DISC formation and caspase activation. The extrinsic pathway interconnects with the intrinsic pathway via the mitochondria with proteins like Bid acting as a bridge between them. The engagement of these pathways highlights DR4’s importance in regulatory mechanisms of cell death tightly controlling cellular proliferation and survival.
DR4 plays a significant role in cancer and autoimmune diseases. Alterations in DR4 expression or function can lead to evasion of apoptosis by cancer cells contributing to tumor progression. The defective apoptotic signaling via DR4 is also linked to autoimmune disorders where insufficient apoptosis may allow for the survival of autoreactive immune cells. In both scenarios DR4's involvement usually associates with its counterpart DR5 as they share similar ligand-binding properties and signal transduction mechanisms in diseased states.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com